Multi-Center, Open Label, Dose Escalating, Sequential Group Study to Assess the Hemodynamic Effects, Safety and Tolerability of CD-NP in Patients With Stabilized Acute Heart Failure (AHF)

Trial Profile

Multi-Center, Open Label, Dose Escalating, Sequential Group Study to Assess the Hemodynamic Effects, Safety and Tolerability of CD-NP in Patients With Stabilized Acute Heart Failure (AHF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2009

At a glance

  • Drugs Cenderitide (Primary)
  • Indications Acute heart failure
  • Focus Therapeutic Use
  • Acronyms PreCONDITION
  • Most Recent Events

    • 04 Aug 2009 Interim results are expected later in 2009 and full results in 2010 according to a Nile Therapeutics media release.
    • 04 Aug 2009 First patient has been dosed according to a Nile Therapeutics media release.
    • 15 May 2009 Nile Therapeutics has reported that the US FDA has released the CD-NP development programme from clinical hold.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top